Navigation Links
Drug Tarceva for End-stage Lung cancer

Patients with end-stage lung cancer who were given Tarceva lived longer than patients// given a placebo.

Lung cancer is the most common cancer occurring both in men and women. Two studies were conducted by Canadian –led international research team with recruits from all over the world.

The first study was conducted by Dr. Timothy Winton of the University of Alberta conducted his study in 482 patients. The study was done to prove that if chemotherapy is given to lung cancer patients after surgery, the survival rate of these patients is high. Surgeries prior to chemotherapy improved cure rate, 69% of the recruits are still alive five years later, compared with 54% who just had surgery. Overall, survival rate was 94 months for the study recruits compared to 73 months for those who had surgery alone.

A new drug Tarceva, generically know as erlotinib has undergone a phase 3 trial in patients with end-stage lung cancer, the study was conducted by researchers at Princess Margaret Hospital in Toronto and the results were published in New England Journal of Medicine, the study recruited 731 patients from around the world 488 patients received Tarceva and 243 patients were given a placebo. Patients who took Tarceva survived an average of 6.7 months, while placebo patients survived an average of 4.7 months. Though, the average months seem to be low, but you have to understand that Tarceva is given to end-stage lung cancer patients, who have no other chemotherapy options. It should also be noted that up to 15 % of patients lived longer than 2 years on the drug, compared to no one lived longer than 2 years taking placebo.

Though the figures are not so impressive we have to think this drug as a prospective drug as has an effective drug for treating early-stage lung cancer as it easy to cure compared to end-stage lung cancer.

Tarceva is one of the new class of drug that slows down tumor growth by arresting the specific cellular pathwa y that regulates the cell division. Dosage is 1 pill once a day. Tarceva not only increased the survival rate but also had no side effects and improved the quality of life. Patients taking Tarceva had only little symptoms of pain, shortness of breath and coughing, rash and diarrhea which can be easily managed.

“This is very significant because this is the first time that any treatment has been shown to prolong survival for patients with lung cancer after they've failed chemotherapy,” Dr. Shepherd said.

The drug has not yet been approved for use in Canada but was authorized for routine use in patients with advanced lung cancer by the U.S. Food and Drug Administration

Related medicine news :

1. Tarceva Found To Benefit Older Lung Cancer Patients
2. Roche Calls For Re-Examination Of Tarceva Data By EU Authorities
3. Dialysis Trust Set Up in Bangalore by End-stage Kidney Patients
4. Vitamin B12 can help in detecting cancers
5. Want skin cancer? Please have a cigarette
6. New hope for cancer victims – will vaccine cure the deadly bug
7. Clintons new problem - Is the outgoing American president suffering from skin cancer?
8. Are cancer patients being taken for a ride?
9. Breast cancer treatment to be determined by gene test
10. Ductal lavage may detect early breast cancer
11. Beware of the oral patch! It could be cancer!!!
Post Your Comments:

(Date:11/25/2015)... ... , ... In an ongoing Clinical Study conducted by an independent physician, Andrew ... is evaluating the efficacy of its product and its disinfection protocol. This study is ... May 2014 through October 2015 at a 360-bed, acute-care, academic medical center located in ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... found that regular bras were incredibly uncomfortable," said an inventor from Bronx, N.Y. ... , She developed the patent-pending RECOVERY BRA for added comfort and support. The ...
(Date:11/25/2015)... ... November 25, 2015 , ... Since its launch in ... involving adult stem cell therapies to patients with chronic degenerative medical conditions. Now, ... a Registered Trademark (RTM). , Organizations are required to hold a registered trademark ...
(Date:11/24/2015)... ... November 24, 2015 , ... Dr. Todd S. Afferica, a noted general ... many of his patients. Dr. Afferica now uses the BIOLASE WaterLase iPlus 2.0™ in ... time the doctor uses other traditional cutting tools, such as the scalpel and high-speed ...
(Date:11/24/2015)... ... 2015 , ... In an article published November 12th by Obesity ... are or are not eligible for bariatric surgery. The article explains that candidates for ... than 100 pounds overweight, or have a BMI of 35 and over with at ...
Breaking Medicine News(10 mins):
(Date:11/24/2015)... , 24. November 2015 ... Breathing Pacemaker Systems, ist erfreut, die Berufung ... Consultant bekannt geben zu können. ...   --> Foto - ... (Schweden). Von 1984-1986 war er Fellow ...
(Date:11/24/2015)... Avery Biomedical Devices (ABD), manufacturer of the ... appointment of Anders Jonzon , MD; Ph.D. as ... Dr. Jonzon is a Physiologist and consultant ... University, Uppsala and Children,s Hospital, Karolinska, Stockholm, ... at the Cardiovascular Institute (UCSF). His research has covered ...
(Date:11/24/2015)... Inc. (Pink Sheets: ASDS ) ("Ascendant" or the "Company") ... special 1 percent stock dividend on the company,s common stock ... shareholders of record December 7, 2015.  The dividend will be ... --> --> "This ... confidence in Ascendant,s growth strategy as well as the underlying ...
Breaking Medicine Technology: